CA-VELODYNE-LIDAR,-INC.
28.8.2020 14:02:10 CEST | Business Wire | Press release
Velodyne Lidar, Inc. today announced it has joined the Intelligent Transportation Society of America (ITS America) to promote the benefits of autonomous vehicles and intelligent transportation infrastructure. Velodyne is the first lidar technology company to become part of this influential group. ITS America members are at the forefront of driving progress in autonomous vehicles and smart city solutions to help save lives, improve mobility and promote sustainability.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200828005057/en/
Velodyne’s lidar sensors can be used in a variety of Intelligent Transportation Systems to measure and monitor conditions in areas such as pedestrian safety, vehicle traffic and parking space management, and more. They can collect reliable, detailed traffic data about road users, including vehicles, pedestrians and bicyclists, while preserving anonymity. Velodyne’s lidar sensors do not identify individuals’ facial characteristics, a growing requirement for civic applications. In addition to transportation systems, Velodyne’s lidar sensors have a strong presence in autonomous vehicles and advanced driver assistance systems (ADAS).
Velodyne has a long-standing commitment to fostering understanding of the safety and mobility benefits of autonomous vehicles and intelligent infrastructure to consumer, business, government, public safety and community audiences. These efforts include Velodyne’s World Safety Summit on Autonomous Technology . The event has sparked collaborative work to advance solutions for rolling out autonomy and ADAS with the goal of improving safety on the roadways. Velodyne also partners with Mothers Against Drunk Driving (MADD) on public education about improving safety on roadways.
Velodyne’s lidar sensors are used in a rich ecosystem of customers and applications, which is highlighted in the Automated with Velodyne program. Partners in the program provide solutions for smart city, infrastructure, autonomous vehicles and more. Within the program, Velodyne is working to advance research in transportation infrastructure, partnering with University of Nevada, Reno . The university’s Nevada Center for Applied Research, working in conjunction with the Nevada DOT and Nevada Governor’s Office of Economic Development , is using Velodyne’s sensors in its Intelligent Mobility initiative. Velodyne is also partnering with automotive OEMs, and robotaxi and autonomous shuttle companies to enable safe and efficient transportation options for cities. For instance, Voyage has built the technology and services to bring autonomous transportation to those who need it, beginning in retirement communities.
“Lidar is a foundational technology that will help drive intelligent mobility in smart city applications and in vehicles on our roadways,” said Shailen Bhatt, President & CEO, ITS America. “Velodyne has demonstrated a strong commitment and great skills in advancing public knowledge about lidar and how autonomous technology can greatly improve transportation. We welcome their contributions in helping ITS America promote intelligent transportation technologies.”
“Velodyne Lidar is strongly aligned with the ITS America mission to improve mobility, advance safety on the roadways, and increase efficiency in our communities,” said Sally Frykman, VP of Communications, Velodyne Lidar. “We envision companies and government organizations will use Velodyne’s lidar sensors to enable a new generation of smart infrastructure through data collection and the deployment of autonomous vehicles.
About Velodyne Lidar
Velodyne provides smart, powerful lidar solutions for autonomy and driver assistance. Headquartered in San Jose, Calif., Velodyne is known worldwide for its portfolio of breakthrough lidar sensor technologies. Velodyne’s founder, David Hall, invented real-time surround view lidar systems in 2005 as part of Velodyne Acoustics. Mr. Hall’s invention revolutionized perception and autonomy for automotive, new mobility, mapping, robotics, and security. Velodyne’s high-performance product line includes a broad range of sensing solutions, including the cost-effective Puck™, the versatile Ultra Puck™, the autonomy-advancing Alpha Prime™, the ADAS-optimized VELARRAY™, and the groundbreaking software for driver assistance, Vella™.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200828005057/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom